Actively Recruiting
Randomized Double-Blind Trial of ALTO-207 Versus Placebo in Adults With Treatment-Resistant Depression
Led by Alto Neuroscience · Updated on 2026-10-26
178
Participants Needed
63
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adults with treatment-resistant depression TRD to evaluate the effects of ALTO-207 compared with a placebo. This clinical trial aims to measure changes in depressive symptoms, particularly focusing on the Montgomery-sberg Depression Rating Scale MADRS scores over eight weeks. The study is randomized, double-blind, and placebo-controlled, conducted by Alto Neuroscience. Participants receive either ALTO-207 or a matching placebo twice daily BID during the treatment phase. The trial follows a parallel design, comparing the effects of the experimental drug to placebo over the course of the study. Throughout the trial, participants undergo assessments including changes in MADRS scores and clinician-administered Clinical Global Impression-Severity CGI-S scores. The primary outcome is the change from baseline in MADRS total score up to eight weeks. Secondary outcomes include response rates and CGI-S score changes. Safety and adherence are monitored, with a total participation period extending through the eight-week treatment phase and follow-up.
CONDITIONS
Brief Title
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Research Team
A
Alto Neuroscience
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here